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ABSTRACT
Background. More information is needed for selection of
patients with peritoneal metastases from endometrial can-
cer (EC) to undergo cytoreductive surgery (CRS) plus
hyperthermic intraperitoneal chemotherapy (HIPEC).
Methods. This study analyzed clinical, pathologic, and
treatment data for patients with peritoneal metastases from
EC who underwent CRS plus HIPEC at two tertiary cen-
ters. The outcome measures were morbidity, overall
survival (OS), and progression-free survival (PFS) during a
median 5 year follow-up period. Uni- and multivariate
analyses were performed to identify significant factors
related to outcome.
Results. A total of 33 patients met the inclusion criteria
and completed the follow-up period. At laparotomy, the
median peritoneal cancer index (PCI) was 15 (range 3–35).
The CRS procedure required a mean 8.3 surgical proce-
dures per patient, and for 22 patients (66.6%), a complete
cytoreduction was achieved. The mean hospital stay was
18 days, and major morbidity developed in 21% of the
patients. The operative mortality was 3%. When surgery
ended, HIPEC was administered with cisplatin 75 mg/m2
for 60 min at 43 C. During a median follow-up period of
73 months, Kaplan–Meier analysis indicated a 5 year OS
of 30% (median 33.1 months) and a PFS of 15.5% (median
18 months). Multivariate analysis identified the complete-
ness of cytoreduction (CC) score as the only significant
factor independently influencing OS. Logistic regression
for the clinicopathologic variables associated with com-
plete cytoreduction (CC0) for patients with metachronous
peritoneal spread from EC who underwent secondary CRS
plus HIPEC identified the PCI as the only outcome
predictor.
Conclusions. For selected patients with peritoneal metas-
tases from EC, when CRS leaves no residual disease, CRS
plus HIPEC achieves outcomes approaching those for other
indications such as colon and ovarian carcinoma.
Endometrial cancer (EC) is the most common gyneco-
logic cancer in developed countries.1 For low-risk patients
(the majority), primary treatment achieves high overall
cancer-specific survival rates,2,3 whereas for high-risk
patients (20–30% of all those with a new diagnosis),
treatment achieves low survival due to histologically
aggressive tumors, adverse pathologic factors, and
advanced disease at onset, inducing high recurrent disease
rates and accounting for up to 50–60% of all EC-related
deaths.3–6
Another common finding (10–30% overall incidence),
especially among patients with recurrent high-risk EC, is
intraperitoneal involvement, at a single disease site or
combined with hematogenous or lymphatic spread.4,7,8
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Although some reports could underestimate intraperitoneal
spread through a transtubal route in early-stage disease,9,10
peritoneal disease generally involves patients with primary
high-risk advanced-stage EC or those with recurrent
tumors, both of whom have a dismal outlook.3,11,12
Ongoing trials currently are testing whether a combined
approach using cytoreductive surgery (CRS) plus hyper-
thermic intraperitoneal chemotherapy (HIPEC), already
standard care for selected patients with pseudomyxoma
peritonei and peritoneal mesothelioma,13 improves out-
come for peritoneal metastases from colorectal, gastric, and
ovarian cancer, as well as for peritoneal surface malig-
nancies (PSM) originating from other unusual sites.14,15
Although several retrospective series from centers experi-
enced in treating PSM have analyzed the findings for
synchronous or metachronous peritoneal metastases from
EC treated with CRS and HIPEC, the small number of
patients included preclude statistically reliable general
conclusions.16–20 Further insights also are needed on
prognostic factors and the criteria for selecting patients
with peritoneal metastases from EC to undergo CRS and
HIPEC.
We therefore investigated a series of patients who had
peritoneal metastases from EC treated with CRS plus
HIPEC at two tertiary centers experienced in treating PSM.
We specifically aimed to assess the results of the integrated
procedure achieved in this new PSM field to define out-
comes and possible selection criteria more clearly.
The outcome measures were morbidity, overall survival
(OS), and progression-free survival (PFS) during a median
5-year follow-up period. Uni- and multivariate analyses
were performed to identify significant factors related to
outcome.
METHODS
Study Design
We conducted a retrospective multicenter cohort study
of patients from two tertiary centers experienced in treating
PSM. These patients underwent CRS plus HIPEC for
peritoneal metastases from EC during the 14 years, from
November 2002 to April 2016.
Patient Population
Data were entered into a custom-designed database
including only patients whose records contained complete
information including age, Eastern Cooperative Oncology
Group (ECOG) performance status, tumor markers, diag-
nostic techniques, International Federation of Gynecology
and Obstetrics (FIGO) stage,21 tumor histology, peritoneal
cancer index (PCI),22 surgical procedures and complica-
tions (Clavien-Dindo Classification),23 completeness of
cytoreduction (CC) score,22 HIPEC techniques and drugs,
in patients with metachronous peritoneal spread from EC,
data regarding primary treatment, chemotherapy, eventual
drug-induced toxicity during systemic chemotherapy and
HIPEC evaluated with the National Cancer Institute
Common Terminology Criteria for Adverse Events
(CTCAE version 4.0),24 and last, complete, updated data
on follow-up.
The indications for CRS and HIPEC were peritoneal
metastatic spread from advanced or recurrent EC in
patients younger than 75 years with adequate cardiac,
renal, hepatic, and bone marrow function and ECOG per-
formance status 0–2 with resectable disease who had
signed written informed consent. The contraindications
were extra-abdominal disease at CRS plus HIPEC, other
malignancies, unresectable disease, and lack of fitness for
the procedure. The two institutional review boards
approved the study procedures before research activities
started and prospective data collection began.
Preoperative Management
Detailed staging depended chiefly on diagnostic imaging
findings including computed tomography (CT), magnetic
resonance imaging (MRI), and positron emission CT (PET-
CT) combined with laparoscopy if imaging failed to
specify resectability. Patients were scheduled for CRS plus
HIPEC at a multidisciplinary meeting.
CRS and HIPEC
At laparotomy, peritoneal spread was recorded accord-
ing to the PCI.22 Patients then underwent CRS with
peritonectomy procedures and visceral resections intended
to leave no visible disease.25 For patients who had under-
gone laparoscopy, trocar sites were removed by full-
thickness parietal resection. For patients with synchronous
peritoneal spread, CRS included pelvic and paraaortic
lymphadenectomy.26 Patients with metachronous peri-
toneal spread from EC underwent lymphadenectomy if it
had not been performed previously, or if needed for evident
nodal relapse. When surgery ended, HIPEC was adminis-
tered with the closed technique.27
Postoperative Management
All patients entered an intensive care unit (ICU) to
receive prophylaxis for deep venous thrombosis and total
parenteral nutrition until oral calorie intake became ade-
quate. Morbidity was analyzed with the Clavien-Dindo
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classification,23 and operative mortality was defined as
death within 90 days after surgery.
Histopathology and Staging
Histopathology followed the new FIGO and World
Health Organization (WHO) EC classifications including
the dualistic classification proposed by Bokhman.28,29 All
pathology slides underwent central review by a gyneco-
logic pathologist (A.C.).
Follow-up Evaluation
After CRS plus HIPEC, patients received adjuvant
chemotherapy according to their general status and
underwent follow-up evaluation according to a predefined
scheme standardized for both institutions. For the first
2 years, asymptomatic patients were scheduled for clinical
assessment and tumor marker testing every 3 months and
diagnostic imaging every 6 months, and thereafter, clinical
assessment and tumor marker testing every 6 months and
yearly diagnostic imaging. In accordance with Esselen
et al.30 recurrent disease sites after CRS plus HIPEC were
classified as intraperitoneal, extraperitoneal, or distant.
Extraperitoneal recurrences were defined as nodal, as were
intraabdominal sites outside the peritoneal cavity, includ-
ing intraparenchymal recurrences. Supradiaphragmatic
non-nodal disease was classified as a distant recurrence.
Statistical Analysis
Follow-up data were completed 31 December 2016. For
continuous variables, we analyzed number of observations,
median, and range, and for discrete variables, we analyzed
number of observations and frequency. The Mann–Whit-
ney U test was used to compare data in groups. In this
study, OS was defined as the time from CRS plus HIPEC to
the date of death from any cause, and PFS was defined as
the time from CRS plus HIPEC to objective tumor pro-
gression or death from any cause, whichever occurred first.
The study defined PFS2 as the time from CRS plus HIPEC
to the second objective disease progression or death from
any cause, whichever occurred first.31
Both OS and PFS probabilities were estimated using the
Kaplan–Meier method. The log-rank test was used to
compare between-group OS and PFS. The median OS and
PFS and corresponding two-sided 95% confidence intervals
(CIs) for each group were calculated using the Kaplan–
Meier method. Univariate and Cox multivariate regression
analysis models were used to explore the influence of
prognostic factors on OS and PFS. A logistic regression
model was applied to evaluate whether clinicopathologic
variables influenced CC scores. Statistical data were
analyzed with the R statistical software package version
3.3.3. All p values lower than 0.05 were considered to
indicate statistical significance.
RESULTS
The inclusion criteria were met by 36 patients attending
the two participating tertiary centers who underwent CRS
plus HIPEC. Of these 36 patients, 3 were lost to follow-up
evalution. Of the remaining 33 patients, 5 had synchronous
peritoneal metastases, whereas 28 had metachronous peri-
toneal metastases from EC and underwent primary or
secondary CRS, both combined with HIPEC (Table 1).
Three of the five patients for whom laparoscopy confirmed
a PCI higher than 20 underwent six cycles of carboplatin
AUC6 plus paclitaxel 175 mg/m2 every 3 weeks to lower
tumor burden before primary CRS plus HIPEC and had a
partial response (intraoperative PCI\ 10). Of the remain-
ing two patients, one refused NeoAdjuvant ChemoTherapy
(NACT) and one had a low PCI (3) at diagnosis and
directly underwent primary CRS plus HIPEC.
TABLE 1 Demographic and clinical characteristics of the 33
patients with peritoneal metastases from endometrial cancer (EC)
undergoing cytoreductive surgery (CRS) plus hyperthermic
intraperitoneal chemotherapy (HIPEC)
Variables Peritoneal metastases from EC
CRS
Primary Secondary
No. of patients 5 28
Age: years (range) 59 (42–65) 58 (43–73)
CA-125: U/ml (range) 150 (50–450) 230.5 (0–1500)
ECOG performance status
0 4 12
1 1 15
Histology
Type 1
Endometrioid
G2 1 3
G3 1 12
Type 2
Serous 2 8
Clear cell – 2
Carcinosarcoma 1 2
Squamous – 1
Peritoneal cancer index (range) 9 (3–21) 16 (5–35)
Data are expressed as median and range unless otherwise stated
ECOG Eastern Cooperative Oncology Group
Peritoneal Metastases from Endometrial Cancer
Of the 28 patients who underwent secondary CRS with a
median of 17.5 months (range 6–36 months) elapsing after
the first operation, 26 had previously undergone total
hysterectomy and bilateral salpingo-oophorectomy with
locoregional lymphadenectomy (21 pelvic and 5 combined
pelvic and paraaortic lymphadenectomy). These 26 patients
included 13 who had lymphatic spread at primary treatment
and underwent adjuvant chemotherapy using two drugs
(cisplatin and doxorubicin) in eight cases, three drugs
(cisplatin, doxorubicin, and paclitaxel) in three cases. Two
of these patients had a diagnosis of carcinosarcoma using
ifosfamide combined with paclitaxel. Finally, four patients
underwent vaginal brachytherapy, with two of the four
patients receiving combined with adjuvant chemotherapy.
At laparotomy, the median PCI for the 33 patients was
15 (range 3–35), with no significant difference between the
patients who underwent primary CRS and those who had
secondary CRS (p = 0.09, Mann–Whitney U test). Over-
all, 273 surgical procedures were needed to achieve CRS
for the 33 patients. All the patients who underwent primary
CRS had pelvic and paraaortic lymphadenectomy, whereas
after secondary CRS, 10 patients needed further lym-
phadenectomy for suspected nodal relapse. Surgery
achieved complete cytoreduction (CC score, 0) for 22
patients (66.6%), whereas for 11 patients, it left residual
disease as follows: CC1 for 7 patients (21.2%), CC2 for 3
patients (9.1%), and CC3 for 1 patient (3.1%). The mean
hospital stay was 18 days, and major morbidity (grade 3 or
4) developed in 21% of the patients. The overall operative
mortality was 3%, involving one patient who had an
intraoperative massive pulmonary embolism (Table 2).
For 32 patients (excluding the patient who died intra-
operatively of a massive pulmonary embolism), when
surgical procedures ended, HIPEC was administered with a
single drug (cisplatin 75 mg/m2) for 60 min at 43 C. For
two patients (6.2%), HIPEC induced a grade 1 or 2 acute
kidney injury, which medical treatment promptly reversed.
At discharge, after a mean hospital stay of 48 days, 30
patients underwent multi-agent adjuvant chemotherapy
variously integrated with biologic and molecular treatment
for recurrent or metastatic disease. At this writing after a
median follow-up period of 73-months (range
8–141 months; 95% CI 39.05–126.18 months), of the 32
patients who survived after CRS plus HIPEC, 8 are alive
and disease free, 5 are alive with disease, and 19 have died.
Of the 33 patients in this study, 24 had recurrent disease
(involving the peritoneum in 54.1%) and received several
chemotherapy regimens or further surgery (Table 3).
Kaplan–Meier survival analysis showed a 5-year OS rate of
30% and a 5-year PFS rate of 15.5% (Fig. 1a). The median
OS was 33.1 months (PFS 18 months; PFS2 28.2 months).
The patients who underwent complete cytoreduction (CC0)
had a significantly better OS than the patients whose
TABLE 2 Surgical procedures, outcomes, and morbidity
Surgical procedures Cytoreductive surgery
Primary Secondary All
patients
(n = 5) (n = 28) (n = 33)
Peritonectomy
Pelvic 4 18 22
Subtotal 1 10 11
Visceral resections
Pelvic
Histero-adnexectomy 5 – 5
Recurrent pelvic mass – 20 20
Upper vaginectomy – 7 7
Gastrointestinal
Left colon 4 13 17
Right colon – 4 4
Right?left colon – 1 1
Transverse colon – – –
Total colectomy 1 1 2
Small bowel – 19 19
Appendectomy 4 14 18
Gastric – 1 1
Hepatobiliary
Cholecystectomy 2 7 9
Atypical hepatic resection – 2 2
Pancreatic tail – 1 1
Splenectomy 1 8 9
Genitourinary and others
Partial bladder resection – 3 3
Nephrectomy – 1 1
Greater omentectomy 5 28 33
Round?falciform ligament 5 28 33
Implant resection/in situ
destruction
1 25 26
Abdominal wall resection 5 9 14
Lymphadenectomy
Regional 5 10 15
Total 43 230 273
Mean 8.6 8.2 8.3
Outcomes Mean Range
Duration of procedures (min) 375 120–660
Blood loss (ml) 600 100–900
Blood transfusions (U) 3 1–7
Plasma transfusions (U) 4 2–8
ICU stay (h)a 14 8–50
Postoperative stay (days) 18.6 9–90
Surgical morbidity gradeb n %
1–2 10 33.3
3 5 15.1
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surgery left residual disease (p\ 0.016, log-rank test)
(Fig. 1b).
The univariate analysis (log-rank test) for OS identified
the CC score and PCI as the only two factors significantly
influencing outcome. The univariate analysis for PFS
identified the PCI as the only significant factor. The mul-
tivariate Cox regression analysis reevaluating significant
univariate prognostic factors identified the CC score as the
only significant factor capable of independently influencing
OS (Table 4). Logistic regression for the clinicopathologic
variables associated with complete cytoreduction (CC0) in
the 28 patients with metachronous peritoneal spread from
EC who underwent secondary CRS combined with HIPEC
identified the PCI as the only outcome predictor (OR 1.24;
95% CI 1.09–1.53). A one-unit increase in PCI value
increased the risk of a CC score higher than 0 by 24%.
DISCUSSION
This series of patients who had peritoneal metastases
from EC treated with CRS plus HIPEC at two tertiary
centers experienced in treating PSM was relatively large
given that peritoneal metastases from EC involve an unu-
sual site for this combined treatment. Despite the rare
indications and given that treating these patients is a
challenging task, overall, we obtained with accept-
able morbidity, outcome rates generally approaching those
reported for CRS plus HIPEC in other indications.32–34
Our findings in this series of patients with peritoneal
metastases from EC treated with CRS plus HIPEC are hard
to compare with others. Although two collective reviews
report a series of patients who underwent combined treat-
ment for peritoneal metastases from various primary
diseases including EC, they failed to analyze the features of
these patients in detail.15,33 The only homogeneous com-
parison is in the series of 13 patients treated by Delotte
et al.19 These investigators reported a complete cytore-
duction rate analogous to that in our series, but achieved
higher overall survival rates also if the median PCI and
median follow-up period were less than the rates we report
(median PCI, 12 vs. 15; median follow-up period, 19.4 vs.
73 months).
An equally difficult task was to compare our patients
who had advanced or recurrent EC with peritoneal spread
treated using CRS plus HIPEC with other patients who
underwent CRS alone. In the past few years, therapeutic
advances have recommended (e.g., for ovarian cancer)35
maximal cytoreduction aimed at leaving no residual dis-
ease as the cornerstone of every multimodal therapeutic
strategy.36–44 Adjuvant chemotherapy unfortunately seems
poorly effective for patients with advanced high-risk EC,3,6
leading to considerably lower outcome rates than those
obtained for ovarian cancer.45 Precise identification of
metastatic peritoneal disease and quantification of its extent
are factors rarely considered by major case series analyzing
the results obtained with CRS alone for primary advanced
or recurrent EC. Moreover, when studies refer to peritoneal
spread, they usually do so to underscore that this is a
typical site for metastatic spread in high-risk patients,
worsened by an unfavorable outcome.4,6,8 Hence, com-
parison of outcome findings for our patients treated using
CRS plus HIPEC with those for patients who undergo CRS
alone suffers from bias. Bias apart, our outcome results
compare well with published data, especially for those
patients in whom CRS combined with HIPEC achieved
complete cytoreduction.12,37,38,41,42,45,46
Despite a few exceptions,6,46 in our series, compared
with most published series analyzing data for CRS alone in
treating advanced or recurrent EC,37,38,41,42 the only inde-
pendent prognostic factor able to predict outcome was the
completeness of cytoreduction. Although it remains con-
jectural whether HIPEC improved outcome in our series,
an outcome finding that emerged from analysis of the 24
patients who had recurrent disease was the site of recur-
rence. Only 50% of the recurrent disease sites involved the
peritoneum, thus implying that HIPEC might act as a
protective factor. This finding supports what Esselen
et al.30 have already reported for advanced ovarian cancer
treated after CRS with endoperitoneal normothermic
adjuvant chemotherapy.
Our series also provided some help in identifying the
criteria for selecting CRS plus HIPEC to manage peritoneal
metastases from EC. For this purpose, we need to distin-
guish synchronous from metachronous peritoneal
metastases. Despite the few synchronous peritoneal
metastases, NACT reduced peritoneal involvement before
CRS for three of our five patients, and achieved long-term
PFS for the remaining two patients. Given that others have
used NACT in primary advanced EC for no more than 100
patients, it still seems premature to consider NACT
responses as a selection criterion for CRS with HIPEC.47
For the 28 patients with metachronous peritoneal metas-
tases from EC, the logistic regression analysis testing
clinicopathologic factors associated with complete cytore-
duction identified PCI as the only outcome predictor. A
TABLE 2 continued
Surgical morbidity gradeb n %
4 1 3
5 1 3
ICU intensive care unit
ahours
bAccording to Clavien-Dindo classification
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possible PCI cutoff value for selecting patients to undergo
CRS with HIPEC remains open for future research in a
larger cohort.
Because none of our patients with advanced-stage EC
had undergone genomic characterization to identify
molecular biomarkers predicting individual tumor behav-
ior, we cannot say to which molecular EC subgroup their
tumors belonged.48 Nor can we say whether molecular
status explained the wide survival range. Future research
should improve the emerging molecular classification tools
for risk group assessment and avoid wasting resources by
identifying cost-effective molecular-targeted therapy.49
The limitations of our study were its retrospective
design and the small number of patients enrolled. During
the natural history of EC, only 15–30% of patients have
peritoneal metastatic spread, precluding prospective ran-
domized-controlled trials.39
In conclusion, for patients with peritoneal metastases
from EC, especially when CRS leaves no residual disease,
CRS plus HIPEC administered in experienced centers for
properly selected cases achieves OS and PFS outcome rates
approaching those for the most frequent indications for this
combined procedure (colorectal or ovarian cancer).32,34,50
Given that positive peritoneal cytology is a risk factor for
peritoneal relapse and that some suggest including
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FIG. 1 a Kaplan–Meier curves for overall survival (OS) and
progression-free survival (PFS) of the 33 patients with peritoneal
metastases from endometrial cancer who underwent cytoreductive
surgery (CRS) plus hyperthermic intraperitoneal chemotherapy
(HIPEC). b Kaplan–Meier curves for overall survival (OS) by the
completeness of cytoreduction (CC) score of the 33 patients with
peritoneal metastases from endometrial cancer who underwent CRS
plus HIPEC
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omentectomy in staging high-risk EC,9,11,26,51 HIPEC plus
CRS might help to prevent peritoneal spread in EC.
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